Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars Pathway Seen As Part Of Health Care Reform Debate Next Year

Executive Summary

The potential for cost savings from biosimilars is likely to entangle the debate over a pathway for their approval into the discussion on health care reform that will unfold in the next Congress

You may also be interested in...

Obama Budget Counts On FOB Savings For Health Reform – But How, And How Much, Are Open Questions

FDA would receive funds to create infrastructure for allowing drug reimportation, under sketch of 2010 budget.

Senate Biosimilars Bill Readied For Take-Off In Next Congress

Kennedy will enter 111th Congress with a ready-to-go bill after committee officially reports out S. 1695 last week.

Biosimilars Create Class-wide Competition, German Experience Finds

Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts